Amgen (AMGN) Completes Acquisition of Alantos
7/17/2007 11:40:41 AM
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos’s DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6.
comments powered by